Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 401–500 of 1,002
Innate immune mediators in cancer: between defense and resistance
Berraondo, P., Minute, L., Ajona, D., Corrales, L. P., Melero, I., & Pío, R. (2016) · Immunological Reviews · doi:10.1111/imr.12464 · Cited by 146
Verheyden, S., Schots, R., Duquet, W., & Demanet, C. (2005) · Leukemia · doi:10.1038/sj.leu.2403839 · Cited by 148
Popat, U., Mehta, R. S., Rezvani, K., Fox, P. S., Kondo, K., Marín, D., McNiece, I., Oran, B., Hosing, C. M., Olson, A. L., et al. (2015) · Blood · doi:10.1182/blood-2015-01-607366 · Cited by 132
“Median (range), years 42 (20-68) 49 (15-65) .”
Mouse Models of Bone Marrow Transplantation
Reddy, P. R., Negrin, R. S., & Hill, G. R. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.10.021 · Cited by 130
“Novel immune cell subsets other than donor T cells—NK, NKT, and host dendritic cells—have been shown to modulate GVL [50-52].”
BackgroundKawase, T., Matsuo, K., Kashiwase, K., Inoko, H., Saji, H., Ogawa, S., Kato, S., Sasazuki, T., Kodera, Y., & Morishima, Y. (2008) · Blood · doi:10.1182/blood-2008-08-171934 · Cited by 130
Yoon, S. R., Lee, Y. S., Yang, S., Ahn, K. H., Lee, J.-H., Lee, J.-H., Kim, D. Y., Kang, Y., Jeon, M., Seol, M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.304 · Cited by 129
Improving Engraftment and Immune Reconstitution in Umbilical Cord Blood Transplantation
Danby, R., & Rocha, V. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00068 · Cited by 153
“In HLAhaploidentical transplants, donor-versus-recipient NK-cell alloreactivity also protects against rejection, GvHD, and acute myeloid leukemia (AML) relapse (88, 89).”
BackgroundJuric, M. K., Ghimire, S., Ogonek, J., Weissinger, E. M., Holler, E., van Rood, J. J., Oudshoorn, M., Dickinson, A. M., & Greinix, H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00470 · Cited by 170
“GvH NK alloreactivity was associated with significantly improved survival, favored engraftment, eradication of AML, and reduced GvHD (131, 132).”
BackgroundReceptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans
Du, Z., Gjertson, D. W., Reed, E. F., & Rajalingam, R. (2006) · Immunogenetics · doi:10.1007/s00251-006-0168-4 · Cited by 134
“For example, interrupting self-tolerance could improve NK cell activity to hematopoietic malignancies (Parham and McQueen 2003; Ruggeri et al. 2002).”
BackgroundLowe, E. J., Turner, V., Handgretinger, R., Horwitz, E. M., Benaim, E., Hale, G. A., Woodard, P., & Leung, W. H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04604.x · Cited by 129
“Ruggeri et al (2002) analysed adult patients who received extensive T-cell-depleted haploidentical grafts.”
BackgroundResultWaller, E. K., Langston, A. A., Lonial, S., Cherry, J., Somani, J., Allen, A. J., Rosenthal, H., & Redei, I. (2003) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(03)00127-7 · Cited by 129
“The high overall mortality observed among the patients entered on this phase I study is not out of proportion with the outcomes expected for these very poor-risk patients with relapsed and refractory leukemia and lymphoma and the absence of KIR mismatching for over half the patients [13].”
ResultBorghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 183
Schrauder, A., Reiter, A., Gadner, H., NIETHAMMER, D., Klingebiel, T. E., Kremens, B., Peters, C., Ebell, W., Zimmermann, M., Niggli, F. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2679 · Cited by 128
de Andrade, L. F., Kumar, S., Luoma, A., Ito, Y., da Silva, P. H. A., Pan, D., Pyrdol, J. W., Yoon, C. H., & Wucherpfennig, K. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0483 · Cited by 137
“Such alloreactiveNKcells are key to the therapeutic efficacy of allogeneic stem cell transplantation for leukemia (37).”
BackgroundCAR‐NK cells: the next wave of cellular therapy for cancer
Daher, M., Garcia, L. M., Li, Y., & Rezvani, K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1274 · Cited by 135
Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), Sanz, J., Galimard, J., Labopin, M., Afanasyev, B. V., Angelucci, E., Ciceri, F., Blaise, D., Cornelissen, J. J., Meijer, E., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00882-6 · Cited by 126
Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M., & Velardi, A. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.007 · Cited by 128
Self-citationMHC-dependent inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling
Kieckbusch, J., Gaynor, L. M., Moffett, A., & Colucci, F. (2014) · Nature Communications · doi:10.1038/ncomms4359 · Cited by 128
“Thus, in allogeneic bone marrow transplantations, engagement of an excess of inhibitory KIR on donor NK by host HLA prevents donor cells from clearing the cancer and ultimately impacts negatively on survival 44 .”
Yu, J., Venstrom, J. M., Liu, X., Pring, J., Hasan, R. S., O’Reilly, R. J., & Hsu, K. C. (2009) · Blood · doi:10.1182/blood-2008-09-177055 · Cited by 135
Laffont, S., Seillet, C., Ortaldo, J. R., Coudert, J. D., & Guéry, J. (2008) · Blood · doi:10.1182/blood-2007-10-120089 · Cited by 137
The Innate NK Cells, Allograft Rejection, and a Key Role for IL-15
Kroemer, A., Xiao, X., Degauque, N., Edtinger, K., Wei, H., Demirci, G., & Li, X. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.7818 · Cited by 142
“Indeed, in bone marrow transplant models, NK cells are potent effector cells in rejection of allogeneic stem cells (10, 11).”
BackgroundSchönberg, K., Sribar, M., Enczmann, J., Fischer, J., & Uhrberg, M. (2011) · Blood · doi:10.1182/blood-2010-03-273656 · Cited by 129
Ojo, E. O., Sharma, A., Liu, R., Moreton, S. A., Checkley-Luttge, M.-A., Gupta, K., Lee, G., Lee, D. A., Otegbeye, F., Sékaly, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51287-6 · Cited by 140
Identification of natural killer cell receptor phenotypes associated with leukemia
Verheyden, S. J., Bernier, M., & Demanet, C. (2004) · Leukemia · doi:10.1038/sj.leu.2403525 · Cited by 138
Szczepański, M. J., Szajnik, M. E., Welsh, A., Foon, K. A., Whiteside, T. L., & Boyiadzis, M. M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0724-5 · Cited by 130
“The enhanced anti-tumor eVect of NK cells is mainly due to the incompatibility between the recipient’s HLA class I antigens and the KIR repertoire expressed by the donor NK cells [24].”
Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis
Moretta, L., Bottino, C., Pende, D., Vitale, M., Mingari, M. C., & Moretta, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.07.004 · Cited by 141
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways
Verhoeven, D. H. J., de Hooge, A. S. K., Mooiman, E., Santos, S. J., ten Dam, M. M., Gelderblom, H. A. J., Melief, C. J. M., Hogendoorn, P. C. W., Egeler, R. M., van Tol, M. J. D., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.016 · Cited by 125
Federmann, B., Bornhäuser, M., Meisner, C., Kordelas, L., Beelen, D. W., Stuhler, G., Stelljes, M., Schwerdtfeger, R., Christopeit, M., Behre, G., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.059378 · Cited by 123
“showed a significant positive impact of the presence of a KIR-ligand mismatch on engraftment and survival.(29,37) However, we could not confirm a survival advantage for patients transplanted from an NK-alloreactive donor in our study.”
Chen, C., Busson, M., Rocha, V., Appert, M.-L., Lepage, V., Dulphy, N., Haas, P., Socié, G., Toubert, A., Charron, D. J., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705468 · Cited by 123
Baessler, T., Charton, J. E., Schmiedel, B. J., Grünebach, F., Krusch, M., Wacker, A., Rammensee, H., & Salih, H. R. (2009) · Blood · doi:10.1182/blood-2009-06-227934 · Cited by 130
Use of NK cell activity in cure by transplant
Leung, W. H. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08823.x · Cited by 138
“…these three definitions of ‘KIR mismatch’ gave rise to three basic models of donor selection to optimize NK cell effects in HSCT: the Perugia KIR ligand model (Ruggeri et al, 2002), the Memphis receptor-ligand model (Leung et al, 2004), and the Stanford KIR haplotype model (McQueen et al, 2007).”
BackgroundMethodInfluentialVago, L., Forno, B., Sormani, M. P., Crocchiolo, R., Zino, E., Terlizzi, S. D., Stanghellini, M. T. L., Mazzi, B. A., Perna, S. K., Bondanza, A., et al. (2008) · Blood · doi:10.1182/blood-2007-07-103325 · Cited by 160
“Median day of first add-back infusion 42 (14-130)”
Pathophysiology of acute graft-versus-host disease: recent advances
Sun, Y., Tawara, I., Toubai, T., & Reddy, P. R. (2007) · Translational research · doi:10.1016/j.trsl.2007.06.003 · Cited by 135
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Lü, H., Zhao, X., Li, Z., Hu, Y., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720501 · Cited by 138
Peccatori, J., Forcina, A., Clerici, D. T., Crocchiolo, R., Vago, L., Stanghellini, M. T. L., Noviello, M., Messina, C., Crotta, A., Assanelli, A. A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.180 · Cited by 129
Huang, X., Zhu, H., Chang, Y., Xu, L., Liu, D., Zhang, X., Jiang, B., Jiang, Q., Jiang, H., Chen, Y., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389809 · Cited by 120
Ogawa, H., Ikegame, K., Yoshihara, S., Kawakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Hasei, H., Kaida, K., Inoue, T., et al. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.06.007 · Cited by 120
Loke, J. C. T., Malladi, R. K., Moss, P. A. H., & Craddock, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16355 · Cited by 134
ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy
Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0303 · Cited by 119
“apymay be an effective approach for patientswith RCC (7), and emerging strategies are currently under investigation based on adoptive transfer of T or NK cells (8, 9).”
BackgroundCD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells
Björkström, N. K., Béziat, V., Cichocki, F. M., Liu, L. L., Levine, J. J., Larsson, S., Koup, R. A., Anderson, S. K., Ljunggren, H., & Malmberg, K. (2012) · Blood · doi:10.1182/blood-2012-03-416867 · Cited by 119
Brennan, T. V., Lin, L., Huang, X., Cardona, D. M., Li, Z., Dredge, K. S., Chao, N. J. A., & Yang, Y. (2012) · Blood · doi:10.1182/blood-2011-07-368720 · Cited by 118
Fauriat, C., Andersson, S., Björklund, A. T., Carlsten, M., Schaffer, M., Björkström, N. K., Baumann, B. C., Michaëlsson, J., Ljunggren, H., & Malmberg, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6010 · Cited by 130
“alloreactive NK cell repertoire in the donor (13).”
BackgroundOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“A noteworthy attribute of mature NK cells in the fi eld of adoptive cell therapy is their ability to retain functionality when transplanted into new environments with differing MHC expression patterns (157, 158).”
BackgroundCritical roles of Bcl11b in T‐cell development and maintenance of T‐cell identity
Liu, P., Li, P., & Burke, S. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00953.x · Cited by 120
Williams, K. M., & Gress, R. E. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.06.003 · Cited by 137
“Some studies have suggested that a graft with KIR mismatch may predict a high probability of NK alloreactivity, augment the graft-versus-AML effect, and diminish the risk of relapse following transplantation.(7,9,29) Unfortunately, for most patients and diseases, the data for this NK-alloreactive effect are limited.”
Morishima, Y., Yabe, T., Matsuo, K., Kashiwase, K., Inoko, H., Saji, H., Yamamoto, K., Maruya, E., Akatsuka, Y., Onizuka, M., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.10.027 · Cited by 117
Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern, M., de Wreede, L. C., Brand, R., van Biezen, A., Dreger, P., Mohty, M., de Witte, T. M., Kröger, N. M., Ruutu, T., & for the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (2014) · Leukemia · doi:10.1038/leu.2014.145 · Cited by 120
Beider, K., Nagler, A., Wald, O., Franitza, S., Dagan-Berger, M., Wald, H., Giladi, H., Brocke, S., Hanna, J., Mandelboim, O., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3293 · Cited by 117
Kröger, N. M., Shaw, B. E., Iacobelli, S., Zabelina, T., Peggs, K. S., Shimoni, A., Nagler, A., Binder, T. M., EIERMANN, T. H., Madrigal, J. A., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05513.x · Cited by 117
“…stem cell transplantation for multiple myeloma was the lower relapse rate for those patients transplanted with a stem cell graft that had KIR-ligand incompatibility in GvH direction, which has been so far only observed for patients with myeloid leukaemias (Ruggeri et al, 2002; Giebel et al, 2003).”
BackgroundMethodNguyen, R., Wu, H., Pounds, S. B., Inaba, H., Ribeiro, R. C., Cullins, D. L., Rooney, B., Bell, T., Lacayo, N. J., Heym, K. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0564-6 · Cited by 120
Immune restoration following hematopoietic stem cell transplantation: an evolving target
Auletta, J. J., & Lazarus, H. M. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704966 · Cited by 129
Müller, S., Bexte, T., Gebel, V., Kalensee, F., Stolzenberg, E., Hartmann, J., Koehl, U., Schambach, A., Wels, W., Modlich, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03123 · Cited by 103
Natural killer cell-based immunotherapy for acute myeloid leukemia
Xu, J., & Niu, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00996-x · Cited by 125
Gurney, M. E., Stikvoort, A., Nolan, E., Kirkham-McCarthy, L., Khoruzhenko, S., Shivakumar, R., Zweegman, S., van de Donk, N. W. C. J., Mutis, T., Szegezdi, É., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.271908 · Cited by 118
“Indeed the potential for long-term disease control, and thus LSC targeting capabilities can be inferred from data establishing the importance of NK cell KIR-ligand mismatch in the efficacy of allogeneic stem cell transplantation.(16) Furthermore, a tandem CAR approach including a LSC-specific antigen and/or a variant…”
BackgroundMcKenna, D. H., Sumstad, D., Bostrom, N., Kadidlo, D. M., Fautsch, S. K., McNearney, S. A., DeWaard, R., McGlave, P. B., Weisdorf, D. J., Wagner, J. E., et al. (2007) · Transfusion · doi:10.1111/j.1537-2995.2006.01145.x · Cited by 117
Domain Shuffling Has Been the Main Mechanism Forming New Hominoid Killer Cell Ig-Like Receptors
Rajalingam, R., Parham, P., & Abi-Rached, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.356 · Cited by 118
“For patients receiving an HLA-mismatched hemopoietic-cell transplant for acute myelogenous leukemia, an alloreactive response directed toward the recipient’s cells and mediated by donor-derived NK cells can help eliminate residual leukemia and prevent graft-vs-host disease (9).”
BackgroundMancusi, A., Ruggeri, L., Urbani, E., Pierini, A., Massei, M. S., Carotti, A., Terenzi, A., Falzetti, F., Tosti, A., Topini, F., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599993 · Cited by 120
“Donor-versus-recipient NK cell alloreactions control leukemia relapse and improve survival in adult and pediatric patients.(13-17,26,27) Homologues of the inhibitory KIRs, with shorter cytoplasmic tails, activating KIRs transduce signals which activate NK cells.”
InfluentialSelf-citationNatural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 125
Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemias
Moretta, A., Locatelli, F., & Moretta, L. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00651.x · Cited by 128
“These pioneering studies by Velardi and colleagues (62, 92) revealed that patients with AML had a greatly improved disease-free survival rate and reduced relapse rates when a KIR-ligand mismatch was present.”
BackgroundCarlsten, M., Baumann, B. C., Simonsson, M., Jädersten, M., Forsblom, A., Hammarstedt, C., Bryceson, Y. T., Ljunggren, H., Hellström‐Lindberg, E., & Malmberg, K. (2010) · Leukemia · doi:10.1038/leu.2010.149 · Cited by 126
“7 Recent evidence suggest that natural killer (NK) cells may contribute to the graft-versus-leukemia effect observed in AML patients following haploidentical stem-cell transplantation”
BackgroundEx vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
Gendzekhadze, K., Norman, P. J., Abi‐Rached, L., Graef, T. T., Moesta, A. K., Layrisse, Z. E., & Parham, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906051106 · Cited by 113
“Following hematopoietic stem cell transplantation for leukemia, NK cells can provide alloreactivity that prevents graftversus-host disease and relapse of leukemia (3).”
BackgroundImmunotherapy in the treatment of non-small cell lung cancer
Sundar, R., Soong, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.005 · Cited by 120
“The inhibition of KIR results in NK cell mediated anti-tumor activity [68].”
Bachanová, V., & Miller, J. S. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011091 · Cited by 122
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Parameswaran, R., Ramakrishnan, P., Moreton, S. A., Xia, Z., Hou, Y., Lee, D. A., Gupta, K., Lima, M. J. G. D., Beck, R. C., & Wald, D. N. (2016) · Nature Communications · doi:10.1038/ncomms11154 · Cited by 121
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 113
“Adoptive cell therapy (ACT) with allogeneic haplo-identical NK cells has been clinically proven to be safe, without the risk of inducing GvHD. NK cells have been shown to be major contributors to the graft-versus-tumor (GvT) response observed after hematopoietic stem cell transplantation (HSCT) for acute myeloid leuke…”
BackgroundKIR Receptors as Key Regulators of NK Cells Activity in Health and Disease
Dębska-Zielkowska, J., Moszkowska, G., Zieliński, M., Zielińska, H., Dukat-Mazurek, A., Trzonkowski, P., & Stefanska, K. A. (2021) · Cells · doi:10.3390/cells10071777 · Cited by 119
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes
Bondanza, A., Valtolina, V., Magnani, Z., Ponzoni, M., Fleischhauer, K., Bonyhadi, M., Traversari, C., Sanvito, F., Toma, S., Radrizzani, M., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3716 · Cited by 115
Dysregulation of Natural Killer Cells in Obesity
O'Shea, D. B., & Hogan, A. E. (2019) · Cancers · doi:10.3390/cancers11040573 · Cited by 124
“Incubation of NK cells isolated from healthy donors with AML blasts induced similar defects suggesting the reported defects were cancer induced [55].”
ResultInfluentialArmand, P. A., Lesokhin, A. M., Borrello, I., Timmerman, J. M., Gutierrez, M. E., Zhu, L., McKiver, M. P., & Ansell, S. M. (2020) · Leukemia · doi:10.1038/s41375-020-0939-1 · Cited by 116
Gutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 131
Villalobos, I. B., Takahashi, Y., Akatsuka, Y., Muramatsu, H., Nishio, N., Hama, A., Yagasaki, H., Saji, H., Kato, M., Ogawa, S., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254284 · Cited by 111
Sivori, S., Carlomagno, S., Falco, M., Romeo, E., Moretta, L., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-10-316125 · Cited by 119
Inhibitor and activator: dual functions for SHIP in immunity and cancer
Kerr, W. G. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05869.x · Cited by 112
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
“Furthermore, the partial mismatch between the donor KIR repertoire and the recipient complement of MHC-I enables donor NK to respond to malignancies that retain normal MHC-I expression.(33,34) Our team at the University of Minnesota performed the first trial using this approach in 2005.”
Zhao, Z., Ding, Y., Tran, L. J., Chai, G., & Li, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196892 · Cited by 112
Moesta, A. K., & Parham, P. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00336 · Cited by 112
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Koehl, U., Kalberer, C. P., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., Lowdell, M. W., Uharek, L., Klingemann, H., Curti, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115178 · Cited by 118
“host disease (GvHD) compared to allogeneic T cells.(3,4) Based on platform lectures on the clinical workshop at the international NK2013 meeting in Heidelberg, Germany, which was the 14th meeting of”
BackgroundWagner, J., Pfannenstiel, V., Waldmann, A., Bergs, J. W. J., Brill, B., Huenecke, S., Klingebiel, T. E., Rödel, F., Buchholz, C. J., Wels, W. S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00676 · Cited by 110
Balsamo, M., Vermi, W., Parodi, M., Pietra, G., Manzini, C., Queirolo, P., Lonardi, S., Augugliaro, R., Moretta, A., Facchetti, F., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201142179 · Cited by 110
Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004) · Human Gene Therapy · doi:10.1089/10430340460732463 · Cited by 110
Kärre, K. (2002) · Science · doi:10.1126/science.1070538 · Cited by 109
Biology and clinical impact of human natural killer cells
Farag, S. S., VanDeusen, J. B., Fehniger, T. A., & Caligiuri, M. A. (2003) · International Journal of Hematology · doi:10.1007/bf02983234 · Cited by 121
“An important observation was that, in addition to having a GVT effect, NK cells mismatched for KIR epitopes in the GVH direction failed to induce GVH disease (GVHD) [114, 115 ].”
BackgroundResultInfluentialHighly activated and expanded natural killer cells for multiple myeloma immunotherapy
Garg, T. K., Szmania, S. M., Khan, J. A., Hoering, A., Malbrough, P., Moreno-Bost, A. M., Greenway, A. D., Lingo, J. D., Li, X., Yaccoby, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056747 · Cited by 116
“NK cells from killer immunoglobulin-like receptor-ligand (KIR-L)-mismatched donors can exert a potent anti-leukemic effect and are highly effective in preventing relapse after haplo-identical T-cell-depleted allogeneic peripheral blood stem cell transplantation in patients with relapsed acute myeloid leukemia with a l…”
BackgroundKHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck, G., Branch, D., Smyth, M., Miller, R. G., Vergidis, J., Fahim, S., & Keating, A. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.06.024 · Cited by 106
“and was translated recently into a novel immunotherapy [41].”
BackgroundInfusions of Allogeneic Natural Killer Cells as Cancer Therapy
Leung, W. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1766 · Cited by 120
“The first model was proposed by the Perugia group (7); the ligand mismatch model requires typing HLA in both donor and recipient.”
BackgroundNew views on natural killer cell-based immunotherapy for melanoma treatment
Burke, S., Lakshmikanth, T., Colucci, F., & Carbone, E. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.003 · Cited by 124
Cellular and molecular interactions of mesenchymal stem cells in innate immunity
Maria Spaggiari, G., & Moretta, L. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2012.62 · Cited by 107
Dendritic cell vaccination and immune monitoring
Aarntzen, E. H. J. G., Figdor, C. G., Adema, G. J., Punt, C. J. A., & de Vries, I. J. M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0553-y · Cited by 107
“Clinical studies on adoptive NK-cell immunotherapy have shown that NK cells can target human tumors [45, 52 ].”
Diversity of tissue-resident NK cells
Peng, H. C., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.006 · Cited by 123
Kärre, K., & Zerrahn, J. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0087 · Cited by 107
Locatelli, F., Pende, D., Mingari, M. C., Bertaina, A., Falco, M., Moretta, A., & Moretta, L. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00015 · Cited by 113
“This expectation was only partly confirmed by clinical results, since among adult patients affected by AML, a subgroup of patients given T cell-depleted HSCT from an HLA-disparate relative had a particularly low risk of leukemia relapse (Aversa et al., 1998; Ruggeri et al., 2002).”
BackgroundResultInfluentialHarnessing NK Cell Memory for Cancer Immunotherapy
Fehniger, T. A., & Cooper, M. A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.005 · Cited by 111
Ishikawa, T., Okayama, T., Sakamoto, N., Ideno, M., Oka, K., Enoki, T., Mineno, J., Yoshida, N., Katada, K., Kamada, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31285 · Cited by 108
“Thus, NK cells are important to control tumor development, and the ability of NK cells to kill tumor targets has been extensively studied in various hematological malignancies.(4,5) While clinical results in the cure of hematological malignancies are excellent, NK-based immunotherapy against solid tumors is still limi…”
BackgroundLiu, W., Xiao, X., Demirci, G., Madsen, J. C., & Li, X. C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102997 · Cited by 108
Gill, S., Olson, J. A., & Negrin, R. S. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.01.019 · Cited by 108
“In total, 112 patients with high-risk AML, of whom 61 were in remission and 51 in relapse, were transplanted with HLA-haploidentical grafts from 51 NK alloreactive or 61 nonalloreactive related donors.”
BackgroundInfluentialBoukouaci, W., Busson, M., de Latour, R. P., Rocha, V., Suberbielle, C., Bengoufa, D., Dulphy, N., Haas, P., Scieux, C., Amroun, H., et al. (2009) · Blood · doi:10.1182/blood-2009-04-217430 · Cited by 108
“GVHD prophylaxis CSA, n (%) 6 (3) CSA MTX, n (%) 175 (83) CSA others, n (%) 23 (11) Unknown, n (%) 7 (3) Conditioning TBI-based, n (%) 87 (41) Bu-based, n (%) 124 (59)”
GVHD pathophysiology: is acute different from chronic?
Toubai, T., Sun, Y., & Reddy, P. R. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.02.005 · Cited by 114
Guo, M., Hu, K., Yu, C., Sun, Q., Qiao, J., Wang, D., Liu, G.-X., Sun, W.-J., Wei, L., Sun, X., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288506 · Cited by 106
Denis, L., Sivula, J., Gourraud, P., Kerdudou, N., Chout, R., Ricard, C., Moisan, J., Gagne, K., Partanen, J., & Bignon, J. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00473.x · Cited by 120
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.